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Abstract: This study was designed to investigate the distribution of Th17 cells in the tumor 
microenvironment  and  peripheral  blood  of  pancreatic  cancer  patients,  its  clinical 
significance, and the expression profile of Th17 cell-associated cytokines. The percentage  
of Th17  cells detected  by  flow  cytometry  analysis (FACS)  was significantly  higher in  
46 pancreatic tumor tissues (5.28 ± 1.65%) compared with corresponding adjacent normal 
tissues  (2.57  ±  0.83%)  (P  =  0.031).  In  addition,  the  percentage  of  Th17  cells  was 
significantly higher in stage III-IV tumors than stage I-II tumors (P = 0.039). The percentage 
of  Th17  cells  in  peripheral  blood  of  20  pancreatic  cancer  patients  (3.99  ±  1.15%)  
was  significantly  higher  than  15  healthy  volunteers  (1.98  ±  0.57%)  (P  =  0.027). 
Immunohistochemistry (IHC) was performed to detect IL-17
+ cells in 46 pancreatic tumor 
tissues, as well as expression of CD34 in 24 tumor tissues. IL-17 was shown to mainly locate 
in cytoplasm, and the frequency of IL-17
+ cells in tumor tissues (39/46) was higher than 
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control (29/46). The presence of IL-17
+ cells in tumor tissues was associated with tumor, 
node, and metastasis (TNM) stage, and lymph node metastasis (P = 0.012 and P = 0.009) 
but not with patient sex, age, tumor size, and histological grade (P > 0.05). Interestingly, 
distribution of Th17 cells in tumor tissues was positively correlated with microvessel density 
(MVD) (r = 0.86, P = 0.018). Furthermore, the median survival time of patients with high 
and low level of IL-17
+ cells frequency was 14.5 and 18.5 months respectively (P = 0.023). 
The  serum  levels  of  Th17  cell-associated  cytokines,  IL-17  and  IL-23  in  20  pancreatic 
patients detected by enzyme-linked immunosorbent assay (ELISA) were 69.2 ± 28.5 pg/mL and 
266.5 ± 98.1 pg/mL, respectively, which were significantly higher than 15 healthy volunteers 
(P = 0.015 and P = 0.02). Moreover, levels of IL-17 and IL-23 were significantly higher in 
stage III-IV tumors than stage I-II tumors (P = 0.04 and P = 0.036). This study suggests that 
increase in Th17 cells frequency and its related cytokines levels in pancreatic tumor tissues 
may indicate involvement in the invasion and metastasis of pancreatic cancer, which may 
thereby affect patient prognosis. Therefore, Th17 cells and related cytokines may be served 
as important immune indicators for predicting the prognosis of pancreatic cancer patients. 
Keywords:  pancreatic  cancer;  Th17  cell;  IL-17;  tumor  microenvironment;  
angiogenesis; prognosis 
 
1. Introduction 
Pancreatic cancer is a gastrointestinal malignancy that is a serious threat to human health. The 
5-year survival rate of pancreatic cancer is less than 5%, giving pancreatic cancer patients the poorest 
prognosis among the malignant cancers [1,2]. Pancreatic cancer is often difficult to diagnose in the 
early stages; only 10–15% of patients are eligible for surgical treatment at diagnosis. Current clinical 
treatments for pancreatic cancer have limited efficacy, highlighting the need for improved treatment 
strategies to prolong patient survival [3,4]. 
Therapies targeting the immune system may represent a promising strategy for the treatment of 
pancreatic cancer [5,6]. Recently, the role of immune mechanisms in pancreatic cancer has led to   
the  development  of  novel  immune  therapeutic  targets  that  have  become  the  focus  for  pancreatic   
cancer treatment. 
Tumor cells can proliferate indefinitely, evade apoptosis, promote angiogenesis, invade tissues, and 
metastasize. The non-tumor components in the tumor microenvironment can participate in regulating 
these complicated processes [7,8]. Immune cells are one of the most important components of the 
tumor microenvironment [9]. Substantial evidence indicates that the abundance of tumor infiltrating 
lymphocytes in the microenvironment of certain tumor types is associated with the prognosis of cancer 
patients, and CD4
+ T cells play a central role in regulating the immune response through their capacity 
to  coordinate  the  functions  of  other  immune  cell  types.  Newly  discovered  CD4
+IL-17
+ cells,  also 
named Th17 cells, are an effector CD4
+T cell subset distinct from Th1, Th2 and Treg cells [10,11]. 
Th17  cells  can  produce  the  cytokine  IL-17,  which  has  been  shown  to  play  a  key  role  in  the 
pathogenesis of autoimmune disorders and infectious diseases [12–14]. An expanding body of studies Int. J. Mol. Sci. 2011, 12                         
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indicates that Th17 cells are present at tumor sites such as ovarian cancer and prostate cancer [15,16]. 
However, the distribution and function of Th17 cells in the pancreatic tumor microenvironment has not 
been well characterized. 
In  our  research,  we  analyzed  the  distribution  of  Th17  cells  in  pancreatic  tumor  tissues  and 
peripheral  blood  of  patients  and  evaluated  the  expression  profile  of  related  cytokines.  We  further 
explored the correlation between the distribution of Th17 cells in the tumor microenvironment and 
tumor angiogenesis, clinical pathological characteristics and patient prognosis. 
2. Results and Discussion 
2.1. Distribution of Th17 Cells in Pancreatic Tumor Tissues as Detected by Flow Cytometry   
Analysis (FACS) 
The  expressions  of  IL-17  in  tumor  infiltrating  lymphocytes  (TIL)  and  non-tumor  infiltrating 
lymphocytes (NIL) were positive, as detected by FACS. However, CD4
+ cells expressed the majority 
of IL-17, and CD8
+ cells expressed little IL-17 in lymphocytes. The frequency of Th17 cells was   
5.28 ± 1.65% in the 46 pancreatic tumor tissues which was significantly higher (P = 0.031) than in the 
corresponding adjacent normal tissues (2.57 ± 0.83%) (Figure 1A, B). Moreover, the frequency of 
Th17 cells in pancreatic tumors of stages III-IV (5.63 ± 1.71%) was significantly higher (P = 0.039) 
than those of stages I-II (3.69 ± 1.40%) (Figure 1C). 
Figure 1. Distribution of Th17 cells in pancreatic tumor tissues. (A) Percentage of Th17 
cells in TIL (n = 46) of pancreatic tumors and NIL (n = 46) of corresponding adjacent 
normal tissues,
 * P = 0.031; (B) Representative FACS data from the percentage of Th17 
cells in TIL and NIL; (C) Percentage of Th17 cells in TIL and NIL of different stages 
(stage I-II: n = 22, stage III-IV: n = 24) of pancreatic tumors, * P = 0.039. 
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2.2. Distribution of Th17 Cells in the Peripheral Blood of Pancreatic Cancer Patients as Detected   
by FACS   
We  also  evaluated  the  presence  of  Th17  cells  in  the  peripheral  blood  of  20  pancreatic  cancer 
patients  and  15  healthy  volunteers.  The  frequency  of  Th17  cells  in  the  peripheral  blood  of  the   
20  pancreatic  cancer  patients  (3.99  ±  1.15%)  was  significantly  higher  (P  =  0.027)  than  in  the 
peripheral blood of the 15 healthy volunteers (1.98 ± 0.57%) (Figure 2A,B). However, the frequency 
of circulating Th17 cells was significantly lower than in tumor tissues from the same patient (data not 
shown), which suggests that Th17 cells accumulated in tumor tissues or that Th17 cells may have 
migrated from the peripheral blood to the tumor tissue in pancreatic cancer patients. 
Figure 2. Distribution of Th17 cells in the peripheral blood of pancreatic cancer patients; 
(A) Percentage of Th17 cells in the peripheral blood of pancreatic cancer patients (n = 20) 
and in controls (n = 15), * P = 0.027; (B) Representative FACS data from the percentage 
of Th17 cells in the peripheral blood of pancreatic cancer patients and in controls. 
 
2.3. Expression of IL-17 in Pancreatic Tumors of Pancreatic in Situ as Detected by Immunohistochemisrty 
(IHC) and Its Correlation with Clinical Pathological Characteristics 
IL-17
 was expressed as brown particles distributed in the cytoplasm of tumor cells (Figure 3). Of 
the 46 pancreatic tumors, 39 were IL-17
+ (84.8%). However, in corresponding adjacent normal tissues, 
only  29  out  of  46  were  IL-17
+  (63%),  although  this  decrease  was  not  statistically  significant   
(P = 0.268). The frequency of IL-17
+ cells in the 22 stage I-II pancreatic tumors was (3.98 ± 0.45%) 
which was significantly lower (P = 0.012) than in the 24 stage III-IV tumors (5.97 ± 1.25%). The 
frequency of IL-17
+ cells in the 35 pancreatic tumors with lymph node metastasis (6.18 ± 1.64%) was 
significantly higher (P = 0.009) than in the 11 patients without lymph node metastasis (3.74 ± 0.55%). 
Taken together, the frequency of IL-17
+ cells
 correlated with TNM stage and lymph node metastasis 
but did not correlate with sex, age, tumor size and histological stage of the patients (P > 0.05) (Table 1). Int. J. Mol. Sci. 2011, 12                         
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2.4. Expression Levels of Serum IL-17 and IL-23 Detected by Enzyme Immunoassays (ELISA)   
We also investigated the expression levels of Th17 cell-associated cytokines in serum, serum levels 
of IL-17 and IL-23 in pancreatic cancer patients were significantly higher than in healthy volunteers 
(IL-17:  69.2  ±  28.5  pg/mL  vs.  14.5  ±  6.8  pg/mL,  P  =  0.015;  IL-23:  266.5  ±  98.1  pg/mL  vs.   
95.1 ± 37.2 pg/mL, P = 0.02). The results are consistent with the increased percentage of Th17 cells in 
peripheral blood mononuclear cells (PBMC) of pancreatic cancer patients. Moreover, serum levels of 
IL-17 and IL-23 in stage III-IV patients were significantly higher (P = 0.04 and P = 0.036) than in 
stage I-II patients (Table 2, Figure 4). 
Figure 3. Expression of IL-17 in pancreatic tumors. IL-17
+ cells stained brown and were 
present in tumor tissues and in corresponding adjacent normal tissues; (A) Representative 
immunostaining  for  high  distribution  of  IL-17
+  cells  is  shown  in  pancreatic  tumors 
(original magnification 400×); (B) Representative immunostaining for low distribution of 
IL-17
+ cells is shown in corresponding adjacent normal tissues (original magnification 400×). 
 
Table 1. Correlation between levels of IL-17
+ cells in pancreatic tumor tissues and clinical 
pathological characteristics. 
Clinic pathological parameters  Cases (n)  Frequency of IL-17
+ cells (%, mean ± SD)  P value 
Sex       
Male  31  4.36 ± 0.85   
Female  15  4.12 ± 0.97  0.408 
Age (years)       
≤60  17  4.45 ± 0.72   
>60  29  4.78 ± 0.91  0.184 
Tumor size (cm)       
≤2  32  4.33 ± 0.75   
>2  14  4.91 ± 0.90  0.298 
Histological grade       
Well differentiated  12  4.35 ± 0.57   
Moderate differentiated  15  4.46 ± 0.71  0.315 
Poor differentiated  19  4.70 ± 0.80   
TNM stage       
Stage I-II  22  3.98 ± 0.45   
Stage III-IV  24  5.97 ± 1.25  0.012 
Lymph node metastasis       
Positive  35  6.18 ± 1.64   
Negative  11  3.74 ± 0.55  0.009 Int. J. Mol. Sci. 2011, 12                         
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Table 2. Levels of serum IL-17 and IL-23 in pancreatic cancer patients (pg/mL, mean ± SD). 
Group  Cases (n)  IL-17  IL-23 
Healthy volunteer  15  14.5 ± 6.8  95.1 ± 37.2 
Pancreatic cancer patient  20  69.2 ± 28.5 *  266.5 ± 98.1 * 
Stage I-II  11  59.1 ± 25.9 *  227.4 ± 87.6 * 
Stage III-IV  9  75.8 ± 29.0 *  279.9 ± 102.1 * 
Note: * P = 0.015 and P = 0.02, compared with healthy volunteers. 
Figure 4. Levels of serum IL-17 and IL-23 in different stages (stage I-II: n = 11, stage III-IV: 
n  =  9)  of  pancreatic  cancer  patients.  *  P  =  0.04  and  P  =  0.036,  compared  with   
control, respectively. 
 
2.5. Correlation between the Distribution of Intratumoral Th17 Cells and Tumor Angiogenesis   
Vascular endothelial cells were detected using a mouse anti-human CD34 monoclonal antibody; 
tumor angiogenesis was evaluated by calculating microvessel density (MVD). Distribution of Th17 
cells and was significantly correlated with MVD in 24 pancreatic tumor tissues, as determined by the 
Pearson correlation analysis (r = 0.86, P = 0.018) (Figure 5). This suggests that Th17 cells might be 
involved  in  tumor  angiogenesis  and  in  the  promotion  of  vascular  formation  of  pancreatic  tumors, 
thereby further facilitating tumor proliferation and metastasis. 
2.6. Correlation between Levels of Intratumoral IL-17
+ Cells and Survival Time of Pancreatic   
Cancer Patients   
Of the 46 pancreatic cancer patients, follow up was successful for 42 (91.3%). The follow up period 
was  5–48  months,  and  the  mean  survival  time  of  these  patients  was  17.5  ±  8.9  months.  Patients   
with  higher  levels  of  intratumoral  IL-17
+ cells  had  significantly  shorter  (P  =  0.023)  survival  time   
(median, 14.5 months) than patients with lower levels of intratumoral IL-17
+ cells (median, 18.5 months) 
(Figure 6). Therefore, an abnormal high frequency of IL-17
+ cells in pancreatic tumor tissues was 
correlated with poor prognosis. Int. J. Mol. Sci. 2011, 12                         
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Figure 5. Correlation between distribution of Th17 cells in pancreatic tumor tissues and 
MVD;  (A)  Representative  immunostaining  of  CD34  in  tumor  tissues  from  patients   
with  a  low  percentage  (2.86%)  of  Th17  cells  in  TIL  (original  magnification  200×);   
(B) Representative immunostaining of CD34 in tumor tissues from patients with a high; 
percentage  (9.15%)  of  Th17  cells  in  TIL  (original  magnification  200×);  (C)  Positive 
correlation between distribution of Th17 cells in pancreatic tumor tissues and MVD (n = 24). 
 
Figure 6. Correlation between levels of IL-17
+ cells in pancreatic tumor tissues and patient 
survival (n = 46). Survival curves of 46 pancreatic cancer patients with different IL-17 
levels are shown. Kaplan-Meier survival curves for high intratumoral expression of IL-17 
group were significantly different (P = 0.023, log-rank test) from the low expression group. 
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2.7. Discussion 
Upon  activation  and  expansion,  naïve  CD4
+ T  cells  develop  into  different  T  cell  subsets  with 
different cytokine profiles and distinct effector functions which include Th1, Th2, Treg and Th17 cells. 
Th17  cells  are  a  recently  discovered  type  of  effector  T  cell  [7,8].  The  role  of  Th17  cells  in 
tumorigenesis has become a focus of attention as their function in autoimmune disorders and infectious 
diseases  has  gradually  been  clarified.  Both  experimental  animal  models  and  clinical  studies  have 
suggested functions for Th17 cells and its related cytokines in tumor development [14–19], but it is not 
yet  clear  for  the  specific  roles  of  Th17  cells  and  the  mechanism  of  their  involvement  in   
tumor immunity. 
To elucidate the roles of Th17 cells and IL-17 in the development of pancreatic cancer, one must 
first understand the distribution of Th17 cells in pancreatic cancer patients. In our study, we detected 
Th17 cells in pancreatic tumor tissues by FACS and showed that the frequency of Th17 cells was 
significantly higher in pancreatic infiltrating lymphocytes than in adjacent infiltrating lymphocytes, 
which was also associated with tumor stages. Japanese researchers [20] showed that Th17 and Treg 
cells accumulate in the tumor microenvironment in early stage gastric cancer patients and that the 
infiltration of Th17 cells decreased gradually as the cancer progressed, whereas the infiltration of Treg 
cells increased. However, our results were discrepant with this study, which may be due to the different 
biological characteristics among different tumor types [21]. In addition, the mechanism for regulating 
the balance of Th17/Treg cells in the tumor microenvironment needs to be further elucidated. 
In contrast to our results, it has previously been shown that certain tumors have decreased levels of 
Th17  cells.  The  levels  of  tumor-infiltrating  Th17  cells  and  IL-17  were  lowered  in  the  ascites  of 
advanced  ovarian  cancer  patients,  which  may  have  a  positive  effect  on  the  prognosis  of  the   
patients [22]. HER2-positive breast cancer patients had decreased levels of Th17 cells compared with 
HER2-negative  patients  and  with  healthy  controls  [23].  A  study  on  prostate  cancer  showed  that 
tumor-infiltrating Th17 cells were negatively correlated with the Gleason score [24], which indicates 
that Th17 cells might result in an anti-tumor immune response. Here, we analyzed the distribution of 
Th17 cells in the peripheral blood of pancreatic cancer patients and showed that the frequency of Th17 
cells was higher in patients than in healthy volunteers. Moreover, the frequency of Th17 cells was 
significantly lower in peripheral blood than in tumor tissues from the same patient, which suggests that 
Th17 cells may accumulate in tumor tissues or Th17 cells may migrate from the peripheral blood to 
the tumor. Therefore, the mechanism of migration and accumulation of Th17 cells into the tumor 
microenvironment  is  worth  further  investigation,  as  Th17  cells  have  been  shown  to  be  closely 
associated with certain key cytokines and chemokines [15,18]. 
IL-17 is a characteristic effector cytokine produced by Th17 cells. IL-17 has six family members 
(IL-17A  to  IL-17F),  and  the  IL-17  receptor  (IL-17R)  family  includes  five  members  (IL-17RA  to 
IL-17RE). The biological function of Th17 cells is closely associated with its secreted IL-17 [25,26]. 
As a member of IL-12 family, IL-23 is the major promoting factor in Th17 cells differentiation and is 
involved in proliferation and long-term survival of Th17 cells [27]. Using ELISA, we found that levels 
of IL-17 and IL-23 in the serum of pancreatic cancer patients were significantly higher than in control 
samples, and these increased levels were associated with tumor stages. Our results suggest that Th17 
cells may be involved in pancreatic tumorigenesis through the secretion of associated cytokines. Int. J. Mol. Sci. 2011, 12                         
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To further study the function of Th17 cells in pancreatic tumorigenesis, we examined the expression 
of  IL-17  in  pancreatic  tumors  and  analyzed  the  correlation  between  IL-17
+  cells  and  clinical 
pathological  characteristics.  We  show  that  a  higher  frequency  of  IL-17
+  cells
 was  correlated  with 
increasing TNM stage and with lymph node metastasis. This suggests that the expression level of 
IL-17 was closely associated with tumor proliferation and invasion and that abnormal expression of 
IL-17 can reflect the potential for pancreatic tumor invasion and metastasis. The formation of new 
tumor vasculature is not only required for tumor growth but is also the primary method of tumor cell 
invasion and metastasis. We show that the frequency of Th17 cells in tumor tissues was positively 
correlated  with  MVD,  suggesting  that  Th17  cells  accumulate  in  tumor  tissues  and  enhance  the 
pro-inflammatory  response  in  the  tumor  microenvironment,  facilitating  tumor  angiogenesis.  As  a 
pro-angiogenic factor, IL-17 has been shown in vitro to stimulate vascular endothelial cell migration 
and cell cord formation as well as to promote tumor angiogenesis, thereby facilitating tumor growth 
and  metastasis  [28].  Charles  et  al.  [29]  showed  that  TNF-α  and  IL-17  promote  tumor  growth 
synergistically in a mouse ovarian cancer model and in tumor patients. Wang et al. [30] showed that 
IL-17 functions to promote tumors through the IL-6-STAT3 signaling pathway. IL-23 can also stimulate 
angiogenesis by upregulating the expression of IL-17 and matrix metalloproteinase 9 (MMP9), as well as 
by decreasing the levels of anti-tumor CD8
+ T cells in the tumor microenvironment. Therefore, our 
findings suggest that the accumulation of Th17 cells in pancreatic tumor tissues and the promotion of 
tumor angiogenesis may be mechanisms of promoting tumor growth, invasion and metastasis. Lastly, 
to  confirm  the  correlation  between  levels  of  IL-17
+ cells  and  the  prognosis  of  pancreatic  cancer 
patients, we assessed the survival time of these patients. We showed that increased levels of IL-17
+ 
cells were significantly correlated with decreased survival times, which indicates that IL-17 may be a 
prognostic indicator for pancreatic cancer. 
An anti-tumor effect of Th17 cells has been reported, in addition to its pro-tumor effects. In a mouse 
pancreatic cancer model, Gnerlich et al. [31] showed that certain cytokines can regulate the Th17/Treg 
balance in the tumor microenvironment. Increases in IL-6 in a TGF-β-rich tumor microenvironment 
can induce the differentiation of CD4
+T cells to Th17 cells, and increase the IFN-γ
+CD8
+T cell number. 
Differentiation to Th17  cells inhibited tumor growth and increased the  survival rate of mice with 
pancreatic cancer. Similar studies have shown that anti-tumor immunity can be strengthened by the 
over-expression of Th1 and Th17 cells in pancreatic cancers, by hybrid vaccines produced by dendritic 
cells and tumor fusion cells, and by Treg cell depletion [32]. In addition, Th17 cells can induce the 
production of the Th1-type inflammatory chemokines CXCL9 and CXCL10, recruiting effector cells 
to the tumor microenvironment which may contribute to anti-tumor immunity. Therefore, it has been 
speculated that Th17 cells mediate tumor rejection by transforming gradually to Th1-type cells in the 
tumor microenvironment [33]. However, the specific function of Th17 cells in tumor immunity is still 
controversial, and it is possible that the function of Th17 cells may vary according to different cancer 
cause, type, and location, as well as stage of the cancer. Additional studies on the regulation and 
transformation mechanisms between Th17 cells and other immune cells may elucidate the role of Th17 
cells in tumor immunity. 
 Int. J. Mol. Sci. 2011, 12                         
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3. Materials and Methods 
3.1. Patients and Specimens 
Tissue from 46 pancreatic tumors was collected at the Department of General Surgery, the First 
Affiliated Hospital of Soochow University. Patients had not received radiotherapy, chemotherapy or 
immune therapy, and patients with autoimmune or infectious diseases were excluded by preoperative 
examination. Patient ages ranged from 43–75 years, with the average age at 61 ± 1.5 years old. Patients 
consisted of 31 males and 16 females. There were 7 stage I, 15 stage II, 18 stage III and 6 stage IV 
tumors according to the pancreatic cancer TNM stage criteria of American Joint Committee on Cancer 
(AJCC,  2007).  According  to  histological  grade,  there  were  12  well  differentiated,  15  moderately 
differentiated and 19 poorly differentiated adenocarcinoma cases. The corresponding adjacent normal 
tissues  were  used  as  controls.  Fresh  specimens  were  resected  under  sterile  conditions,  and  two 
identical portions were prepared. One portion was fixed in 10% neutral formaldehyde, stained with 
H&E and analyzed by IHC; the other portion was used for FACS. Peripheral blood was collected from 
20 out of the 46 patients and 15 healthy volunteers. Collection of all the samples was approved by the 
Independent Ethics Committee (IEC) of the hospital and was consented to by the patients. Patient 
survival was assessed through phone calls and clinic visits. Survival time was defined as the period 
from surgery to last visit or death. 
3.2. Main Reagents 
PC7-labeled  mouse  anti-human  CD4  antibody  (Anti-CD4-PC7),  PE-labeled  mouse  anti-human 
IL-17 antibody (Anti-IL-17-PE) and the Cytofix/Cytoperm kit were purchased from Beckman, USA. 
Goat anti-human IL-17 antibody and donkey anti-goat IgG were purchased from R&D, USA. Phorbol 
myristate acetate (PMA), ionomycin and Golgi antagonist Brefeldin A (BFA) were purchased from 
Sigma, USA. Mouse anti-human CD34 monoclonal antibody was purchased from Beijing Zhongshan 
Biotechnology Co., Ltd, China. Human IL-17 and IL-23 ELISA kits were purchased from Bender 
Medsystems, Austria. 
3.3. Flow Cytometry Analysis 
TIL and NIL were isolated from tissue samples by mechanical methods, and PBMC were acquired. 
PBMC were isolated from the heparinized blood of patients and healthy volunteers. The PBMC were 
cultured in RPMI 1640 medium that contained 100 U/mL penicillin, 100 U/mL streptomycin and 10% 
fetal bovine serum. Cell density was adjusted to 2 × 10
6 c/mL. Cells were stimulated by adding 50 ng/mL 
PMA, 1 µg/mL ionomycin and 10 µg/mL BFA to the medium for 5 h at 37 °C, 5% CO2. Then, 5 µL 
Anti-CD4-PC7, 100 µL cytoperm and 5 µL Anti-IL-17-PE were added sequentially to the cells. Cells 
were resuspended in PBS and analyzed by FACS. Th17 levels were defined as the percentage of 
CD4
+IL-17
+ cells in CD4
+ T cells. Int. J. Mol. Sci. 2011, 12                         
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3.4. Immunohistochemisrty 
The distribution of IL-17
+ cells and the expression of CD34 in tumor tissues were detected by IHC. 
Tumor samples were fixed in 10% neutral formaldehyde, embedded in paraffin, sliced and stained with 
H&E.  Briefly,  the  paraffin-embedded  tissues  were  serially  cut  into  4  µm  sections,  dewaxed,  and 
rehydrated. Sections were then blocked with peroxide and non-immune animal serum and incubated 
sequentially with primary antibody, biotin-labeled secondary antibody, and streptomycin anti-biotin 
peroxidase. Finally, the sections were stained with DBA, counterstained with hematoxylin, dehydrated, 
cleared in xylene, and fixed. Known specimens with positive staining were used as positive controls; 
negative controls were generated by replacing the primary antibody with PBS. To evaluate positive 
results, 5 fields with condensed IL-17 expression were selected under low magnification (100×) and 
cell numbers were counted under high magnification (400×). Cells with cytoplasm stained brown were 
defined as IL-17
+ cells [17]. Vascular endothelial cells or clusters of brown-stained cells were defined 
as microvasculature as long as they formed clear boundaries with adjacent capillaries, tumor cells or 
other connective tissue [34]. The mean value of IL-17
+ cells and the density of CD34 were calculated 
in the 5 selected fields. The median value of IL-17
+ cells was used to categorize the 46 tumor tissues 
into IL-17
+ high and low frequency groups [35]. 
3.5. Enzyme Immunoassays 
The serum of patients and healthy volunteers were analyzed for the Th17-related cytokines IL-17 
and  IL-23  using  ELISA,  following  the  manufacturer’s  instructions.  All  samples  were  measured   
in duplicate. 
3.6. Statistical Analysis 
All  data  are  presented  as  mean  ±  SD  and  were  analyzed  with  SPSS  software  (version  13.0). 
Comparisons between groups were performed by Student’s t-test. The correlation between Th17 cells 
in  tumor  tissues  and  MVD  was  determined  by  Pearson  correlation  analysis,  and  the  correlation 
between IHC results and clinical pathological characteristics was determined by Fisher’s exact test. 
Survival curves were drawn by the Kaplan-Meier method and were compared with the log-rank test. 
Values of P < 0.05 were considered significant. 
4. Conclusions 
In summary, we have identified the levels and distribution of Th17 cells and its associated cytokines 
in the tumor microenvironment and in the peripheral blood of pancreatic cancer patients. We have 
analyzed  the  correlation  between  levels  of  IL-17
+ cells  and  tumor  angiogenesis  and  with  clinical 
pathological characteristics, and have confirmed that different distribution of IL-17
+ cells in tumor 
tissues was closely associated with patient prognosis. Our study has provided an experimental basis for 
further exploring the mechanisms of Th17 cells in pancreatic tumorigenesis and for establishing an 
intervention strategy with Th17 cells as a target. Int. J. Mol. Sci. 2011, 12                         
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